Re: ‘High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients’

We carefully read the article by Cantini et  al. [1]. This is an interesting study that evaluated the association between statin use and clinical outcomes of programmed cell death 1 (PD-1) use using a prospective database. If statins improve clinical outcomes in patients treated with PD-1 inhibitors, treatment strategies for malignant pleura l mesothelioma (MPM) and advanced non-small cell lung cancer (aNSCLC) will dramatically change. Furthermore, this study suggests that those who do not take statins may have a worse overall survival after the use of PD-1 inhibitors for both MPM and aNSCLC, highlighting the importance of pre-treatment cardiovascular risk assessment before treatment with PD-1 inhibitors.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research